-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects of BRAF Mutations on Non-small Cell Lung Cancer Outcomes and Therapeutic Selection
Posted: June 2017 By David Planchard, MD, PhD What was the rationale for conducting clinical research in BRAF mutationpositive NSCLC? Recently, progress has been made in characterization of the oncogenic driver mutations that contribute to the molecular pathogenesis of lung cancers, including activating mutations in EGFR and ALK rearrangements. Moreover, lung cancer has one of…
-
IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer
Posted: June 2017 Despite very encouraging progress in the development and use of immunotherapy for patients with non-small cell lung cancer, much confusion remains regarding patient selection for each therapy. Programmed cell death ligand-1 (PD-L1) protein expression, as detected by immunohistochemistry (IHC) testing, has been widely used as a predictive biomarker assay for anti-PD-1/PD-L1 therapies.…
-
IASLC Thoracic Oncology (2nd ed.)
Posted: June 2017 For the past 40 years the International Association for the Study of Lung Cancer has remained the only society exclusively dedicated to the study and treatment of lung cancer and other thoracic malignancies. These cancers are notoriously complicated, as was recently pointed out by their mutational burdens and histologic heterogeneity. New discoveries,…
-
NCI Corner – Interview with Matthew Holderfield, PhD
Posted: June 2017 NCI to Team Up with Cancer Research UK and the Cancer Research Technology Pioneer Fund on RAS Research On April 19, 2017, Cancer Research UK (CRUK) and the Cancer Research Technology (CRT) Pioneer Fund announced a commitment of £2.5 million, or about $3.2 million, for a collaboration with the National Cancer Institute…
-
Breaking News Briefs
• Pembrolizumab (Keytruda) received FDA approval for use in combination with pemetrexed and carboplatin for the first-line treatment of patients with metastatic nonsquamous NSCLC, irrespective of PD-L1 expression. This approval was based on randomized phase II data from KEYNOTE-021, Cohort G1, in 123 previously untreated patients with metastatic nonsquamous NSCLC and no evidence of EGFR…
-
Deb Violette, Lung Cancer Survivor and Advocate: Her Story
Posted: June 2017 Editor’s note: IASLC Lung Cancer News is committed to including the patient’s voice and experience of having lung cancer as part of our editorial breadth and mission. Here we are pleased to present Deb Violette’s story. A courageous advocate and longterm survivor of lung cancer, Ms. Violette is also the president and…
-
Dziadziuszko Follows in Footsteps of Thoracic Oncology Icon, Receives Award in Heine Hansen’s Name
Posted: June 2017 By Keightley Amen, BA, ELS In 2015, the International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO) established an annual award to recognize Heine H. Hansen’s lifetime of international contributions to lung cancer research and education. This year, the HHH Award was bestowed upon…
-
2017 ASCO Annual Meeting
Posted: June 2017 By Erik J. MacLaren, PhD The Annual Meeting of the American Society of Clinical Oncology (ASCO) is taking place June 2–6 in Chicago, Illinois, and over 5,000 abstracts have been accepted for presentation at the meeting or for online release. The theme of this year’s meeting is Making a Difference in Cancer…
-
FDA Corner – Interview with Commander Jason Humbert
Posted: June 2017 FDA Warns of Fraudulent Cancer Drugs On April 25, 2017, the US Food and Drug Administration (FDA) issued warning letters to 14 companies regarding more than 65 products being marketed with unproven or fraudulent claims. The products identified included pills, topical creams, ointments, oils, drops, syrups, teas, and a thermography device.1 The…
-
European Perspective on Molecular Testing
Posted: June 2017 By Νiki Karachaliou, MD, PhD The identification of oncogenic driver alterations in non-small cell lung cancer (NSCLC), such as EGFR mutations and ALK rearrangements, each of which confers sensitivity to small tyrosine kinase inhibitors, has made EGFR and ALK testing a necessity in routine molecular pathologic diagnosis. Furthermore, next-generation sequencing (NGS) studies…